Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III–IV melanoma in phase III trial E1609

[1]  D. Cella,et al.  Validity of a single-item indicator of treatment side effect bother in a diverse sample of cancer patients , 2022, Supportive Care in Cancer.

[2]  D. Schadendorf,et al.  Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Gray,et al.  Predictive value of bother by side effects of treatment prior to protocol therapy for early treatment discontinuation in clinical trials. , 2020 .

[4]  Christopher T. Chan,et al.  Development of the Functional Assessment of Cancer Therapy–Immune Checkpoint Modulator (FACT‐ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs , 2020, Cancer.

[5]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[6]  V. Sondak,et al.  Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Hauschild,et al.  Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. , 2019, The New England journal of medicine.

[8]  J. Beaumont,et al.  Validity and usefulness of a single‐item measure of patient‐reported bother from side effects of cancer therapy , 2018, Cancer.

[9]  T. Whelan,et al.  Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03) , 2018, Breast Cancer Research and Treatment.

[10]  Jeffrey E Gershenwald,et al.  Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.

[11]  D. Schadendorf,et al.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.

[12]  Amy P Abernethy,et al.  Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[14]  H. Pehamberger,et al.  Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  A. Maraveyas,et al.  A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma , 2009, Clinical Cancer Research.

[16]  D. Eton,et al.  Combining Distribution- and Anchor-Based Approaches to Determine Minimally Important Differences , 2005, Evaluation & the health professions.

[17]  A. Gnanasakthy,et al.  Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[18]  B. Redman,et al.  Validation of the FACT-BRM with interferon-alpha treated melanoma patients. , 2005, Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation.

[19]  B. Redman,et al.  Validation of the FACT-BRM with interferon-α treated melanoma patients , 2005, Quality of Life Research.

[20]  R. Motzer,et al.  The functional assessment of cancer therapy–BRM (FACT–BRM): A new tool for the assessment of quality of life in patients treated with biologic response modifiers , 2004, Quality of Life Research.

[21]  David Cella,et al.  The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation , 2003, Health and quality of life outcomes.

[22]  V. Sondak,et al.  High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Atkins,et al.  High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  V. Sondak,et al.  High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Kirkwood,et al.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[27]  S. Jasko,et al.  Therapy , 1881, The American journal of dental science.